<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-17011948</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-07-11</date_registration>
      <primary_sponsor>Bone Marrow Transplantation Center of the First Affiliated Hospital,College of Medicine, Zhejiang University</primary_sponsor>
      <public_title>A single-arm prospective study on treatment of myelodysplastic syndromes and acute myeloid leukemia associated with myelodysplastic syndromes with chemotherapy plus HLA mismatched peripheral blood stem cell transplantation</public_title>
      <acronym />
      <scientific_title>A single-arm prospective study on treatment of myelodysplastic syndromes and acute myeloid leukemia associated with myelodysplastic syndromes with chemotherapy plus HLA mismatched peripheral blood stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-08-01</date_enrolment>
      <type_enrolment />
      <target_size>study group:30;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=20112</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Myelodysplastic syndromes and </hc_freetext>
      <i_freetext>study group:chemotherapy plus HLA-mismatched donor's hematopoitic stem cells infusion;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Jie Sun</firstname>
        <middlename />
        <lastname />
        <address>79 Qingchun Street, Hangzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 15305714109</telephone>
        <email>jsun1492@zju.edu.cn</email>
        <affiliation>Bone Marrow Transplantation Center of the First Affiliated Hospital,College of Medicine,Zhejiang University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Jie Sun</firstname>
        <middlename />
        <lastname />
        <address>79 Qingchun Street, Hangzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 15305714109</telephone>
        <email>jsun1492@zju.edu.cn</email>
        <affiliation>Bone Marrow Transplantation Center of the First Affiliated Hospital,College of Medicine,Zhejiang University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Patients are diagnosed as AML-MRC and High-risk MDS according to the 2016 WHO diagnostic criteria;
2. Patients are not suitable or not willing to undergo allogeneic hematopoietic stem cell transplantation;
3. Patients are willing to bear the cost of decitabine and does not have decitabine allergy histor;
4. Patients have suitable donor willing to donate stem cells (HLA haploidentical or not matched healthy donors;
5. Patients or legal representative have signed informed consent before clinical study start.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>75</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Patients does not meet the diagnostic criteria;
2. patients with severe liver and kidney function, cardiorespiratory insufficiency;
3. uncontrolled or severe infection;
4. there may be a mental illness that may prevent subjects from completing treatment or informed consent.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>complete remission;1 year's OS;2-year OS;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>partial remission;total response rate;relapse rate;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National nature and science foundation (81372031)</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-02-23</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>